AOCI at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s AOCI?
- Immix Biopharma, Inc. (IMMX) reported AOCI of $105.64K in Q1 2026.
- How has Immix Biopharma, Inc.'s AOCI changed year-over-year?
- Immix Biopharma, Inc.'s AOCI increased by 583.2% year-over-year, from $15.46K to $105.64K.
- What is the long-term trend for Immix Biopharma, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s AOCI has grown at a -14.5% compound annual growth rate (CAGR), from $131.86K to $60.16K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.